

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Creso Pharma Limited
ABN	609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Bruce Linton
Date of appointment	17 January 2022

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Bruce Linton <The Linton Family 2040 A/C>	30,000,000 CPHOPT33 Unlisted Options (\$0.039, 23/12/2025)

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Subject to the continued service of Mr Bruce Linton, the Board will also seek approval of shareholders at its general shareholder meeting for a grant of Options to Mr Bruce Linton (or his nominees). The grant for which approval will be sought will be for 10,000,000 options with an exercise price of 9c and an expiry date that is two years following the Director's commencement date.
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	10,000,000 Unlisted Options (\$0.09, 17 Jan 2024)

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Creso Pharma Limited
ABN	609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Micheline MacKay
Date of appointment	17 January 2022

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Nil	Nil

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
---------------------------	-----

+ See chapter 19 for defined terms.

Appendix 3X
Initial Director's Interest Notice

Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Creso Pharma Limited
ABN	609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	William Lay
Date of appointment	17 January 2022

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Noble House Consulting Ltd (a director related entity)	5,000,000 Ordinary Shares 1,666,667 CPHO Listed Options (\$0.25, 2/11/2024) 10,000,000 CPHOPT41 Unlisted Options (\$0.18, 6/09/2024) 10,000,000 CPHOPT42 Unlisted Options (\$0.25, 6/09/2024) 15,000,000 CPHPERR43 Performance Rights (Nil, 17/09/2023)

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	<p>Subject to shareholder approval, Mr William Lay (or his nominee) is entitled to receive the following equity securities:</p> <ul style="list-style-type: none">• 7,500,000 Performance Rights that will vest upon Creso achieving \$30 million in annual group revenue within 24 months of Mr Lay's appointment as CEO and Managing Director; and• 10,000,000 Unlisted Options, each with an exercise price of \$0.20 and an expiry date that is two years from the date of Mr Lay's appointment as CEO and Managing Director. The Options shall vest and become exercisable on the first anniversary of Mr Lay's appointment, subject to Mr Lay's continuous employment at that date.
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	7,500,000 Performance Rights (Nil, 17 Jan 2024) 10,000,000 Unlisted Options (\$0.20, 17 Jan 2024)

+ See chapter 19 for defined terms.